8-K - Denali Therapeutics Inc. (0001714899) (Filer)
Published . Updated .
Key takeaways
- 8-K - Denali Therapeutics filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
- Exposed: DNLI
- Market reaction: DNLI +4.4% after three sessions
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Denali Therapeutics filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
Directly affected
- DNLI Denali Therapeutics-2.0% 15d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Denali Therapeutics belongs to, so it often moves with news about it.
- AMGN Amgen+15.9% 30d
Amgen is a peer of Denali Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+16.4% 30d
Gilead Sciences is a peer of Denali Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna+22.4% 30d
Moderna is a peer of Denali Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- ARGX argenx SE-11.9% 9d
argenx SE is a peer of Denali Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of Denali Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| DNLI | -1.03% | -2.82% | base | +7.44% | +1.18% | +2.90% | +4.44% |
| XLV | -2.42% | +0.36% | base | +3.08% | +0.65% | +0.47% | +2.39% |
| AMGN | -2.03% | +1.07% | base | +3.67% | -0.14% | +0.04% | +0.88% |
| GILD | -4.93% | +2.07% | base | +4.16% | +0.01% | +0.06% | +1.13% |
| MRNA | -6.29% | -2.97% | base | +13.13% | +5.69% | +15.32% | +17.78% |
| ARGX | -1.09% | -0.93% | base | +3.36% | -0.78% | +2.34% | +6.90% |
| RVMD | -2.84% | -1.45% | base | +2.75% | -8.41% | +0.17% | +3.13% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-03 AccNo: 0001714899-26-000107 Size: 333 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
How far Denali Therapeutics (DNLI) has moved since 3 Nov 2026
Since the first closing price after “8-K - Denali Therapeutics Inc. (0001714899) (Filer),” Denali Therapeutics (DNLI) is -9.81%.
| Company | When | Move | Status |
|---|---|---|---|
| AMGN | that day | +3.67% | final price |
| AMGN | the next day | -0.14% | final price |
| AMGN | two days later | +0.04% | final price |
| AMGN | three days later | +0.88% | final price |
| AMGN | three days earlier | +1.07% | final price |
| AMGN | five days earlier | -2.03% | final price |
| ARGX | that day | +3.36% | final price |
| ARGX | the next day | -0.78% | final price |
| ARGX | two days later | +2.34% | final price |
| ARGX | three days later | +6.90% | final price |
| ARGX | three days earlier | -0.93% | final price |
| ARGX | five days earlier | -1.09% | final price |
| Denali Therapeutics (DNLI) | that day | +7.44% | final price |
| Denali Therapeutics (DNLI) | the next day | +1.18% | final price |
| Denali Therapeutics (DNLI) | two days later | +2.90% | final price |
| Denali Therapeutics (DNLI) | three days later | +4.44% | final price |
| Denali Therapeutics (DNLI) | three days earlier | -2.82% | final price |
| Denali Therapeutics (DNLI) | five days earlier | -1.03% | final price |
| GILD | that day | +4.16% | final price |
| GILD | the next day | +0.01% | final price |
| GILD | two days later | +0.06% | final price |
| GILD | three days later | +1.13% | final price |
| GILD | three days earlier | +2.07% | final price |
| GILD | five days earlier | -4.93% | final price |
| MRNA | that day | +13.13% | final price |
| MRNA | the next day | +5.69% | final price |
| MRNA | two days later | +15.32% | final price |
| MRNA | three days later | +17.78% | final price |
| MRNA | three days earlier | -2.97% | final price |
| MRNA | five days earlier | -6.29% | final price |
| RVMD | that day | +2.75% | final price |
| RVMD | the next day | -8.41% | final price |
| RVMD | two days later | +0.17% | final price |
| RVMD | three days later | +3.13% | final price |
| RVMD | three days earlier | -1.45% | final price |
| RVMD | five days earlier | -2.84% | final price |
| XLV | that day | +3.08% | final price |
| XLV | the next day | +0.65% | final price |
| XLV | two days later | +0.47% | final price |
| XLV | three days later | +2.39% | final price |
| XLV | three days earlier | +0.36% | final price |
| XLV | five days earlier | -2.42% | final price |
Congressional trades in the stocks in this story
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $15,001 - $50,000 on 15 Oct 2026. That is 19 days before publication. Filed 2 Nov 2026. View the filing.
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 42 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 69 days before publication. Filed 5 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 85 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Gilbert Cisneros bought Moderna (MRNA), worth $1,001 - $15,000 on 20 Oct 2026. That is 14 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Argenx Se (ARGX), worth $1,001 - $15,000 on 27 Oct 2026. That is 7 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Argenx Se (ARGX), worth $1,001 - $15,000 on 15 Oct 2026. That is 19 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Argenx Se (ARGX), worth $15,001 - $50,000 on 14 Oct 2026. That is 20 days before publication. Filed 10 Nov 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Denali Therapeutics (DNLI)
Companies mentioned with this story
- DNLI Denali Therapeutics
In “8-K - Denali Therapeutics Inc. (0001714899) (Filer),” Denali Therapeutics (DNLI) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> DNLI
How “8-K - Denali Therapeutics Inc. (0001714899) (Filer)” reaches Denali Therapeutics (DNLI)
The 3 Nov 2026 story “8-K - Denali Therapeutics Inc. (0001714899) (Filer)” names Denali Therapeutics (DNLI) because of this story.
Denali Therapeutics (DNLI) is on the page because SEC 8-K filing -> direct issuer disclosure -> DNLI
Price levels for Denali Therapeutics (DNLI)
DNLI traded between 17.54 and 22.18 across 15 sessions. The latest close on file is 18.89.
How strong the case is around Denali Therapeutics (DNLI)
14 out of 100
“8-K - Denali Therapeutics Inc. (0001714899) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.